| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | November 12, 2024 4:30 P.M. |
| Form: | S-1 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | November 12, 2024 4:30 P.M. |
| Form: | S-1 | ||||||
| |||||||
Save time and jump to the most important pieces.
4 - GlucoTrack, Inc. (0001506983) (Issuer)
Rutherford, NJ., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the launch of a "best efforts" public offering of approximately 7,195,000 shares of common stock (or pre-funded warrants in lieu thereof) with each share of common stock (or pre-funded warrant) accompanied by (i) a series A common warrant to purchase one (1) common share at an exercise price of $1.81 per share and (ii) a series B common warrant to purchase one (1) common share at an exercise price of $1.81 per share. The combined offering price of each share of comm
Continuous blood glucose monitor to be among 100+ future-focused presentations at industry investor conference Rutherford, NJ, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the 2024 BioFuture Conference, to be held at Cure in New York City from October 28-30, 2024. Paul V. Goode, President & Chief Executive Officer of Glucotrack, will present on Tuesday, October 29, 2024, at 11:00 AM ET and will hold one-on-one meetings. The presentation will provide an
Updated preclinical data for the continuous blood glucose monitor to be presented at major diabetes technology conference Rutherford, NJ, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that updated preclinical data for its continuous blood glucose monitor ("CBGM") will be presented at the 24th Annual Diabetes Technology Meeting, to be held from October 15-17, 2024, in Burlingame, California. The Diabetes Technology Meeting is a highly regarded forum where the latest advancements in di
Biotech veteran joins Glucotrack's Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes Rutherford, NJ, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced the appointment of John Ballantyne, PhD to its Board of Directors, effective immediately. "We are pleased to welcome John, who has been a long-standing supporter of the Company, to our Board of Directors," said Paul Goode, PhD, President and CEO of Glucotrack. "An entrepreneur himself, John
Glucotrack expands leadership team with clinical trial expertise for the continuous blood glucose monitor for people with diabetes Rutherford, NJ, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Sandie Martha has joined the Company as Vice President of Clinical Operations. "Sandie brings a wealth of knowledge and expertise to the team in leading clinical trials for both glucose monitoring and cardiology." said Paul Goode, PhD, President and CEO of Glucotrack. "The breadth and depth of
Diabetes industry veteran joins Glucotrack's Board to support bringing novel continuous blood glucose monitoring technology to people with diabetes Rutherford, NJ, June 20, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has appointed Andy Balo to its Board of Directors, effective immediately. Mr. Balo brings decades of regulatory, clinical and quality experience in the medical technology industry. In 2002 he joined Dexcom as part of the original executive team where he remained for the next
1-for-5 reverse stock split to become effective as of the opening of trading onMay 20, 2024 Rutherford, NJ, May 15, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will effect a 1-for-5 reverse stock split (the "Reverse Stock Split") of its issued and outstanding common stock (the "Common Stock"), effective with the opening of trading on Monday, May 20, 2024. Glucotrack's Common Stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "GCTK". The new CUSIP number
4 - GlucoTrack, Inc. (0001506983) (Issuer)
4 - GlucoTrack, Inc. (0001506983) (Issuer)
3 - GlucoTrack, Inc. (0001506983) (Issuer)
SC 13G - Glucotrack, Inc. (0001506983) (Subject)
SC 13G - GlucoTrack, Inc. (0001506983) (Subject)
424B4 - Glucotrack, Inc. (0001506983) (Filer)
8-K - Glucotrack, Inc. (0001506983) (Filer)
EFFECT - Glucotrack, Inc. (0001506983) (Filer)